Clinical  ||| S:0 E:9 ||| JJ
characteristics  ||| S:9 E:25 ||| NNS
of  ||| S:25 E:28 ||| IN
resistant  ||| S:28 E:38 ||| JJ
hypertension  ||| S:38 E:51 ||| NN
in  ||| S:51 E:54 ||| IN
renal  ||| S:54 E:60 ||| JJ
transplant  ||| S:60 E:71 ||| NN
patients  ||| S:71 E:80 ||| NNS
Hypertension  ||| S:80 E:93 ||| NNP
is  ||| S:93 E:96 ||| VBZ
a  ||| S:96 E:98 ||| DT
prevalent  ||| S:98 E:108 ||| JJ
complication  ||| S:108 E:121 ||| NN
that  ||| S:121 E:126 ||| WDT
occurs  ||| S:126 E:133 ||| VBZ
in  ||| S:133 E:136 ||| IN
80-85 ||| S:136 E:141 ||| CD
%  ||| S:141 E:143 ||| NN
of  ||| S:143 E:146 ||| IN
all  ||| S:146 E:150 ||| DT
kidney  ||| S:150 E:157 ||| NN
transplant  ||| S:157 E:168 ||| NN
recipients ||| S:168 E:178 ||| NNS
.  ||| S:178 E:180 ||| .
The  ||| S:180 E:184 ||| DT
pathogenesis  ||| S:184 E:197 ||| NN
of  ||| S:197 E:200 ||| IN
post-transplant  ||| S:200 E:216 ||| JJ
hypertension  ||| S:216 E:229 ||| NN
is  ||| S:229 E:232 ||| VBZ
multifactorial  ||| S:232 E:247 ||| VBN
and  ||| S:247 E:251 ||| CC
includes  ||| S:251 E:260 ||| VBZ
pre-transplant  ||| S:260 E:275 ||| JJ
hypertension ||| S:275 E:287 ||| NN
,  ||| S:287 E:289 ||| ,
donor  ||| S:289 E:295 ||| JJ
hypertension ||| S:295 E:307 ||| NN
,  ||| S:307 E:309 ||| ,
renin  ||| S:309 E:315 ||| JJ
secretion  ||| S:315 E:325 ||| NN
from  ||| S:325 E:330 ||| IN
the  ||| S:330 E:334 ||| DT
native  ||| S:334 E:341 ||| JJ
kidney ||| S:341 E:347 ||| NN
,  ||| S:347 E:349 ||| ,
graft  ||| S:349 E:355 ||| JJ
dysfunction ||| S:355 E:366 ||| NN
,  ||| S:366 E:368 ||| ,
recurrent  ||| S:368 E:378 ||| JJ
disease  ||| S:378 E:386 ||| NN
and  ||| S:386 E:390 ||| CC
immunosuppressive  ||| S:390 E:408 ||| JJ
treatment ||| S:408 E:417 ||| NN
.  ||| S:417 E:419 ||| .
Hypertension  ||| S:419 E:432 ||| NNP
negatively  ||| S:432 E:443 ||| RB
affects  ||| S:443 E:451 ||| JJ
transplant  ||| S:451 E:462 ||| NN
and  ||| S:462 E:466 ||| CC
patient  ||| S:466 E:474 ||| JJ
survival  ||| S:474 E:483 ||| NN
outcomes ||| S:483 E:491 ||| NNS
;  ||| S:491 E:493 ||| :
cardiovascular  ||| S:493 E:508 ||| JJ
disease  ||| S:508 E:516 ||| NN
( ||| S:516 E:517 ||| -LRB-
CVD ||| S:517 E:520 ||| NNP
)  ||| S:520 E:522 ||| -RRB-
is  ||| S:522 E:525 ||| VBZ
the  ||| S:525 E:529 ||| DT
leading  ||| S:529 E:537 ||| JJ
cause  ||| S:537 E:543 ||| NN
of  ||| S:543 E:546 ||| IN
morbidity  ||| S:546 E:556 ||| NN
and  ||| S:556 E:560 ||| CC
mortality  ||| S:560 E:570 ||| NN
in  ||| S:570 E:573 ||| IN
patients  ||| S:573 E:582 ||| NNS
with  ||| S:582 E:587 ||| IN
chronic  ||| S:587 E:595 ||| JJ
renal  ||| S:595 E:601 ||| JJ
disease  ||| S:601 E:609 ||| NN
and  ||| S:609 E:613 ||| CC
after  ||| S:613 E:619 ||| IN
successful  ||| S:619 E:630 ||| JJ
renal  ||| S:630 E:636 ||| JJ
transplantation ||| S:636 E:651 ||| NN
.  ||| S:651 E:653 ||| .
Hypertension  ||| S:653 E:666 ||| NNP
is  ||| S:666 E:669 ||| VBZ
a  ||| S:669 E:671 ||| DT
well-known  ||| S:671 E:682 ||| JJ
risk  ||| S:682 E:687 ||| NN
factor  ||| S:687 E:694 ||| NN
for  ||| S:694 E:698 ||| IN
CVD  ||| S:698 E:702 ||| NNP
and  ||| S:702 E:706 ||| CC
it  ||| S:706 E:709 ||| PRP
is  ||| S:709 E:712 ||| VBZ
frequently  ||| S:712 E:723 ||| RB
associated  ||| S:723 E:734 ||| VBN
with  ||| S:734 E:739 ||| IN
other  ||| S:739 E:745 ||| JJ
CVD  ||| S:745 E:749 ||| NNP
risk  ||| S:749 E:754 ||| NN
factors ||| S:754 E:761 ||| NNS
.  ||| S:761 E:763 ||| .
Despite  ||| S:763 E:771 ||| IN
increased  ||| S:771 E:781 ||| JJ
awareness  ||| S:781 E:791 ||| NN
of  ||| S:791 E:794 ||| IN
the  ||| S:794 E:798 ||| DT
adverse  ||| S:798 E:806 ||| JJ
effects  ||| S:806 E:814 ||| NNS
of  ||| S:814 E:817 ||| IN
hypertension  ||| S:817 E:830 ||| NN
in  ||| S:830 E:833 ||| IN
both  ||| S:833 E:838 ||| DT
graft  ||| S:838 E:844 ||| NN
and  ||| S:844 E:848 ||| CC
patient  ||| S:848 E:856 ||| JJ
survival ||| S:856 E:864 ||| NN
,  ||| S:864 E:866 ||| ,
long-term  ||| S:866 E:876 ||| JJ
studies  ||| S:876 E:884 ||| NNS
have  ||| S:884 E:889 ||| VBP
shown  ||| S:889 E:895 ||| VBN
that  ||| S:895 E:900 ||| IN
arterial  ||| S:900 E:909 ||| JJ
hypertension  ||| S:909 E:922 ||| NN
in  ||| S:922 E:925 ||| IN
the  ||| S:925 E:929 ||| DT
transplant  ||| S:929 E:940 ||| NN
population  ||| S:940 E:951 ||| NN
has  ||| S:951 E:955 ||| VBZ
not  ||| S:955 E:959 ||| RB
been  ||| S:959 E:964 ||| VBN
adequately  ||| S:964 E:975 ||| RB
controlled ||| S:975 E:985 ||| VBN
.  ||| S:985 E:987 ||| .
Resistant  ||| S:987 E:997 ||| JJ
hypertension  ||| S:997 E:1010 ||| NN
( ||| S:1010 E:1011 ||| -LRB-
RH ||| S:1011 E:1013 ||| NNP
)  ||| S:1013 E:1015 ||| -RRB-
is  ||| S:1015 E:1018 ||| VBZ
defined  ||| S:1018 E:1026 ||| VBN
as  ||| S:1026 E:1029 ||| IN
office  ||| S:1029 E:1036 ||| NN
blood  ||| S:1036 E:1042 ||| NN
pressure  ||| S:1042 E:1051 ||| NN
( ||| S:1051 E:1052 ||| -LRB-
oBP ||| S:1052 E:1055 ||| NNP
)  ||| S:1055 E:1057 ||| -RRB-
that  ||| S:1057 E:1062 ||| WDT
remains  ||| S:1062 E:1070 ||| VBZ
above  ||| S:1070 E:1076 ||| IN
goal  ||| S:1076 E:1081 ||| NN
( ||| S:1081 E:1082 ||| -LRB-
oBP  ||| S:1082 E:1086 ||| NNP
â‰¥  ||| S:1086 E:1088 ||| CD
140 ||| S:1088 E:1091 ||| CD
/ ||| S:1091 E:1092 ||| CD
90  ||| S:1092 E:1095 ||| CD
or  ||| S:1095 E:1098 ||| CC
130 ||| S:1098 E:1101 ||| CD
/ ||| S:1101 E:1102 ||| CD
80  ||| S:1102 E:1105 ||| CD
mmHg ||| S:1105 E:1109 ||| NN
)  ||| S:1109 E:1111 ||| -RRB-
in  ||| S:1111 E:1114 ||| IN
patients  ||| S:1114 E:1123 ||| NNS
with  ||| S:1123 E:1128 ||| IN
diabetes  ||| S:1128 E:1137 ||| NN
or  ||| S:1137 E:1140 ||| CC
chronic  ||| S:1140 E:1148 ||| JJ
kidney  ||| S:1148 E:1155 ||| NN
disease  ||| S:1155 E:1163 ||| NN
despite  ||| S:1163 E:1171 ||| IN
the  ||| S:1171 E:1175 ||| DT
concurrent  ||| S:1175 E:1186 ||| JJ
use  ||| S:1186 E:1190 ||| NN
of  ||| S:1190 E:1193 ||| IN
three  ||| S:1193 E:1199 ||| CD
antihypertensive  ||| S:1199 E:1216 ||| CD
agents ||| S:1216 E:1222 ||| NNS
,  ||| S:1222 E:1224 ||| ,
at  ||| S:1224 E:1227 ||| IN
full  ||| S:1227 E:1232 ||| JJ
doses ||| S:1232 E:1237 ||| NNS
,  ||| S:1237 E:1239 ||| ,
one  ||| S:1239 E:1243 ||| CD
of  ||| S:1243 E:1246 ||| IN
them  ||| S:1246 E:1251 ||| PRP
being  ||| S:1251 E:1257 ||| VBG
a  ||| S:1257 E:1259 ||| DT
diuretic ||| S:1259 E:1267 ||| NN
.  ||| S:1267 E:1269 ||| .
Despite  ||| S:1269 E:1277 ||| IN
studies  ||| S:1277 E:1285 ||| NNS
in  ||| S:1285 E:1288 ||| IN
the  ||| S:1288 E:1292 ||| DT
general  ||| S:1292 E:1300 ||| JJ
population  ||| S:1300 E:1311 ||| NN
and  ||| S:1311 E:1315 ||| CC
the  ||| S:1315 E:1319 ||| DT
high  ||| S:1319 E:1324 ||| JJ
prevalence  ||| S:1324 E:1335 ||| NN
of  ||| S:1335 E:1338 ||| IN
hypertension  ||| S:1338 E:1351 ||| NN
in  ||| S:1351 E:1354 ||| IN
renal  ||| S:1354 E:1360 ||| JJ
transplant  ||| S:1360 E:1371 ||| NN
patients ||| S:1371 E:1379 ||| NNS
,  ||| S:1379 E:1381 ||| ,
data  ||| S:1381 E:1386 ||| NNS
about  ||| S:1386 E:1392 ||| IN
RH  ||| S:1392 E:1395 ||| NNP
are  ||| S:1395 E:1399 ||| VBP
very  ||| S:1399 E:1404 ||| RB
scarce  ||| S:1404 E:1411 ||| JJ
and  ||| S:1411 E:1415 ||| CC
the  ||| S:1415 E:1419 ||| DT
prevalence  ||| S:1419 E:1430 ||| NN
of  ||| S:1430 E:1433 ||| IN
RH  ||| S:1433 E:1436 ||| NNP
in  ||| S:1436 E:1439 ||| IN
renal  ||| S:1439 E:1445 ||| JJ
transplant  ||| S:1445 E:1456 ||| NN
patients  ||| S:1456 E:1465 ||| NNS
is  ||| S:1465 E:1468 ||| VBZ
unknown  ||| S:1468 E:1476 ||| JJ
and  ||| S:1476 E:1480 ||| CC
could  ||| S:1480 E:1486 ||| MD
be  ||| S:1486 E:1489 ||| VB
associated  ||| S:1489 E:1500 ||| VBN
with  ||| S:1500 E:1505 ||| IN
a  ||| S:1505 E:1507 ||| DT
worse  ||| S:1507 E:1513 ||| JJR
prognosis ||| S:1513 E:1522 ||| NN
.  ||| S:1522 E:1524 ||| .
